Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities

Detalles Bibliográficos
Autores principales: Dian, Yating, Meng, Yu, Sun, Yuming, Deng, Guangtong, Zeng, Furong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Infection Association. Published by Elsevier Ltd. 2023
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188372/
https://www.ncbi.nlm.nih.gov/pubmed/37207823
http://dx.doi.org/10.1016/j.jinf.2023.05.012
_version_ 1785042899181764608
author Dian, Yating
Meng, Yu
Sun, Yuming
Deng, Guangtong
Zeng, Furong
author_facet Dian, Yating
Meng, Yu
Sun, Yuming
Deng, Guangtong
Zeng, Furong
author_sort Dian, Yating
collection PubMed
description
format Online
Article
Text
id pubmed-10188372
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The British Infection Association. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-101883722023-05-17 Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities Dian, Yating Meng, Yu Sun, Yuming Deng, Guangtong Zeng, Furong J Infect Letter to the Editor The British Infection Association. Published by Elsevier Ltd. 2023-05-17 /pmc/articles/PMC10188372/ /pubmed/37207823 http://dx.doi.org/10.1016/j.jinf.2023.05.012 Text en © 2023 The British Infection Association. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Dian, Yating
Meng, Yu
Sun, Yuming
Deng, Guangtong
Zeng, Furong
Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities
title Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities
title_full Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities
title_fullStr Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities
title_full_unstemmed Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities
title_short Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities
title_sort azvudine versus paxlovid for oral treatment of covid-19 in chinese patients with pre-existing comorbidities
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188372/
https://www.ncbi.nlm.nih.gov/pubmed/37207823
http://dx.doi.org/10.1016/j.jinf.2023.05.012
work_keys_str_mv AT dianyating azvudineversuspaxlovidfororaltreatmentofcovid19inchinesepatientswithpreexistingcomorbidities
AT mengyu azvudineversuspaxlovidfororaltreatmentofcovid19inchinesepatientswithpreexistingcomorbidities
AT sunyuming azvudineversuspaxlovidfororaltreatmentofcovid19inchinesepatientswithpreexistingcomorbidities
AT dengguangtong azvudineversuspaxlovidfororaltreatmentofcovid19inchinesepatientswithpreexistingcomorbidities
AT zengfurong azvudineversuspaxlovidfororaltreatmentofcovid19inchinesepatientswithpreexistingcomorbidities

Ejemplares similares